vs

Side-by-side financial comparison of IDACORP INC (IDA) and IONIS PHARMACEUTICALS INC (IONS). Click either name above to swap in a different company.

IDACORP INC is the larger business by last-quarter revenue ($360.1M vs $203.3M, roughly 1.8× IONIS PHARMACEUTICALS INC). IDACORP INC runs the higher net margin — 12.1% vs -112.8%, a 124.9% gap on every dollar of revenue. On growth, IDACORP INC posted the faster year-over-year revenue change (-4.2% vs -10.3%). IONIS PHARMACEUTICALS INC produced more free cash flow last quarter ($-159.0M vs $-216.2M). Over the past eight quarters, IONIS PHARMACEUTICALS INC's revenue compounded faster (30.4% CAGR vs -7.2%).

IDACORP, Inc is an electricity holding company, incorporated in Idaho with headquarters in Boise. It comprises Idaho Power Company, IDACORP Financial and Ida-West Energy. It was formed on October 1, 1998.

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

IDA vs IONS — Head-to-Head

Bigger by revenue
IDA
IDA
1.8× larger
IDA
$360.1M
$203.3M
IONS
Growing faster (revenue YoY)
IDA
IDA
+6.1% gap
IDA
-4.2%
-10.3%
IONS
Higher net margin
IDA
IDA
124.9% more per $
IDA
12.1%
-112.8%
IONS
More free cash flow
IONS
IONS
$57.2M more FCF
IONS
$-159.0M
$-216.2M
IDA
Faster 2-yr revenue CAGR
IONS
IONS
Annualised
IONS
30.4%
-7.2%
IDA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IDA
IDA
IONS
IONS
Revenue
$360.1M
$203.3M
Net Profit
$43.6M
$-229.4M
Gross Margin
96.1%
Operating Margin
14.9%
-105.5%
Net Margin
12.1%
-112.8%
Revenue YoY
-4.2%
-10.3%
Net Profit YoY
15.1%
-119.8%
EPS (diluted)
$0.78
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDA
IDA
IONS
IONS
Q4 25
$360.1M
$203.3M
Q3 25
$526.4M
$156.7M
Q2 25
$449.3M
$452.0M
Q1 25
$411.1M
$131.6M
Q4 24
$375.9M
$226.6M
Q3 24
$532.5M
$133.8M
Q2 24
$442.6M
$225.3M
Q1 24
$417.9M
$119.5M
Net Profit
IDA
IDA
IONS
IONS
Q4 25
$43.6M
$-229.4M
Q3 25
$124.4M
$-128.6M
Q2 25
$95.8M
$123.6M
Q1 25
$59.6M
$-146.9M
Q4 24
$37.9M
$-104.3M
Q3 24
$113.6M
$-140.5M
Q2 24
$89.5M
$-66.3M
Q1 24
$48.2M
$-142.8M
Gross Margin
IDA
IDA
IONS
IONS
Q4 25
96.1%
Q3 25
98.5%
Q2 25
99.1%
Q1 25
98.9%
Q4 24
98.3%
Q3 24
99.2%
Q2 24
98.2%
Q1 24
98.2%
Operating Margin
IDA
IDA
IONS
IONS
Q4 25
14.9%
-105.5%
Q3 25
27.5%
-102.2%
Q2 25
22.4%
30.9%
Q1 25
13.4%
-111.6%
Q4 24
11.0%
-48.9%
Q3 24
25.1%
-111.1%
Q2 24
23.3%
-29.3%
Q1 24
11.9%
-125.1%
Net Margin
IDA
IDA
IONS
IONS
Q4 25
12.1%
-112.8%
Q3 25
23.6%
-82.1%
Q2 25
21.3%
27.3%
Q1 25
14.5%
-111.6%
Q4 24
10.1%
-46.1%
Q3 24
21.3%
-105.0%
Q2 24
20.2%
-29.4%
Q1 24
11.5%
-119.5%
EPS (diluted)
IDA
IDA
IONS
IONS
Q4 25
$0.78
$-1.35
Q3 25
$2.26
$-0.80
Q2 25
$1.76
$0.70
Q1 25
$1.10
$-0.93
Q4 24
$0.72
$-0.66
Q3 24
$2.12
$-0.95
Q2 24
$1.71
$-0.45
Q1 24
$0.95
$-0.98

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDA
IDA
IONS
IONS
Cash + ST InvestmentsLiquidity on hand
$215.7M
$2.7B
Total DebtLower is stronger
$3.3B
$1.8B
Stockholders' EquityBook value
$3.6B
$489.1M
Total Assets
$10.2B
$3.5B
Debt / EquityLower = less leverage
0.93×
3.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDA
IDA
IONS
IONS
Q4 25
$215.7M
$2.7B
Q3 25
$333.2M
$2.2B
Q2 25
$474.5M
$2.3B
Q1 25
$634.5M
$2.1B
Q4 24
$368.9M
$2.3B
Q3 24
$427.9M
$2.5B
Q2 24
$169.6M
$2.1B
Q1 24
$157.6M
$2.2B
Total Debt
IDA
IDA
IONS
IONS
Q4 25
$3.3B
$1.8B
Q3 25
Q2 25
Q1 25
Q4 24
$3.1B
$1.3B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IDA
IDA
IONS
IONS
Q4 25
$3.6B
$489.1M
Q3 25
$3.5B
$618.0M
Q2 25
$3.4B
$631.7M
Q1 25
$3.3B
$475.7M
Q4 24
$3.3B
$588.4M
Q3 24
$3.3B
$662.5M
Q2 24
$3.2B
$263.7M
Q1 24
$2.9B
$296.5M
Total Assets
IDA
IDA
IONS
IONS
Q4 25
$10.2B
$3.5B
Q3 25
$10.1B
$3.0B
Q2 25
$9.9B
$3.0B
Q1 25
$9.6B
$2.8B
Q4 24
$9.2B
$3.0B
Q3 24
$9.1B
$3.1B
Q2 24
$8.7B
$2.7B
Q1 24
$8.3B
$2.8B
Debt / Equity
IDA
IDA
IONS
IONS
Q4 25
0.93×
3.71×
Q3 25
Q2 25
Q1 25
Q4 24
0.92×
2.13×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDA
IDA
IONS
IONS
Operating Cash FlowLast quarter
$137.8M
$-137.7M
Free Cash FlowOCF − Capex
$-216.2M
$-159.0M
FCF MarginFCF / Revenue
-60.0%
-78.2%
Capex IntensityCapex / Revenue
98.3%
10.5%
Cash ConversionOCF / Net Profit
3.16×
TTM Free Cash FlowTrailing 4 quarters
$-577.5M
$-320.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDA
IDA
IONS
IONS
Q4 25
$137.8M
$-137.7M
Q3 25
$162.8M
$-131.4M
Q2 25
$176.9M
$151.3M
Q1 25
$124.3M
$-150.8M
Q4 24
$136.4M
$-116.1M
Q3 24
$201.9M
$-115.0M
Q2 24
$146.4M
$-119.9M
Q1 24
$109.7M
$-149.9M
Free Cash Flow
IDA
IDA
IONS
IONS
Q4 25
$-216.2M
$-159.0M
Q3 25
$-127.9M
$-136.7M
Q2 25
$-156.4M
$139.0M
Q1 25
$-77.0M
$-163.4M
Q4 24
$-48.9M
$-141.6M
Q3 24
$-16.1M
$-124.0M
Q2 24
$-199.6M
$-126.1M
Q1 24
$-150.3M
$-154.4M
FCF Margin
IDA
IDA
IONS
IONS
Q4 25
-60.0%
-78.2%
Q3 25
-24.3%
-87.2%
Q2 25
-34.8%
30.8%
Q1 25
-18.7%
-124.1%
Q4 24
-13.0%
-62.5%
Q3 24
-3.0%
-92.7%
Q2 24
-45.1%
-56.0%
Q1 24
-36.0%
-129.2%
Capex Intensity
IDA
IDA
IONS
IONS
Q4 25
98.3%
10.5%
Q3 25
55.2%
3.4%
Q2 25
74.2%
2.7%
Q1 25
49.0%
9.6%
Q4 24
49.3%
11.3%
Q3 24
41.0%
6.8%
Q2 24
78.2%
2.8%
Q1 24
62.2%
3.8%
Cash Conversion
IDA
IDA
IONS
IONS
Q4 25
3.16×
Q3 25
1.31×
Q2 25
1.85×
1.22×
Q1 25
2.08×
Q4 24
3.60×
Q3 24
1.78×
Q2 24
1.63×
Q1 24
2.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDA
IDA

Retailrevenues$323.0M90%
Transmissionserviceswheeling$18.6M5%
Energyefficiencyprogramrevenues$11.7M3%
Wholesaleenergysales$10.5M3%
Otherrevenues$9.5M3%

IONS
IONS

Products$58.0M29%
Spinraza Royalties$54.0M27%
Collaborative Agreement Revenue$52.4M26%
Wainus Royalties$16.0M8%
Wainua Joint Development Revenue$9.6M5%
Other Commercial$7.6M4%
Other Royalties$5.7M3%

Related Comparisons